NanoViricides Advances MPox Treatment Amid WHO's Extended Health Emergency
NanoViricides, Inc. progresses with NV-387, a broad-spectrum antiviral drug, as the WHO extends the MPox global health emergency, highlighting the drug's potential to fill gaps in current treatments.
NanoViricides, Inc. (NYSE American: NNVC) has underscored its commitment to combating the MPox virus as the World Health Organization (WHO) prolongs the Public Health Emergency of International Concern (PHEIC). The company's NV-387 drug, having successfully completed Phase I trials with a notable safety record, is now moving towards Phase II trials in Africa. This development is critical, given the limitations of current treatments like tecovirimat and brincidofovir, which have shown restricted effectiveness or undesirable side effects.
NV-387's innovative approach, which mimics human cell characteristics to prevent viral entry, offers a promising alternative that could circumvent resistance issues prevalent with existing therapies. The advancement of NV-387 into Phase II trials not only represents a significant milestone in the fight against MPox but also opens the door to substantial market opportunities, including potential inclusion in government bioterrorism stockpiles. For further details on NanoViricides' progress, visit https://ibn.fm/ZHeZ6.